key: cord-0927918-ifcyovmv
authors: Sookaromdee, Pathum; Wiwanitkit, Viroj
title: COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern on cases with underlying liver problem
date: 2021-09-08
journal: Ann Hepatol
DOI: 10.1016/j.aohep.2021.100525
sha: c69c3a87e45cef9eb457d951b5e304dea33f9ec7
doc_id: 927918
cord_uid: ifcyovmv

nan

Letter to the editor COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern on cases with underlying liver problem We would like to share ideas on the report "COVID-19 vaccineinduced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis [1] ." Aguilar et al. concluded that "We will definitively continue to be updated and "tuned-up" while further research in critical areas like etiopathogenesis and emerging therapies for VITT unfolds in this new fascinating but poorly understood arena of clinical thrombosis...... [1] ." The adverse effect of COVID-19 vaccine is the present focus at present. The thrombohemostatic disturbance might occur. As noted in the editorial, there are many possible pathomechanisms [1] . We would like to add another possible underlying cause of thrombohemostatic disorder, the vaccine-induced hyperviscosity [2] . The rapid increase of immunity after vaccination might occur, and high blood viscosity can alter the normal thromohemostasis process [3] . The problem might arise in anyone receiving the vaccination. For the patient with underlying liver disease, a more risk might be expected.

Of several underlying pathophysiology, many patients with underlying liver disease usually have a high blood bilirubin level. Since hyperbilirubinemia is associated with increased blood viscosity, a patient with underlying liver disease and jaundice, such as cholangiocarcinoma or chronic active hepatitis, might have an increased chance of post COVID-19 vaccination hyperviscosity and thrombohemostatic disorder. Closed monitoring of the possible adverse effect of COVID-19 among a person with underlying jaundice should be required.

None

COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis

Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19

Serum bilirubin and lipoprotein-a: how are these associated with whole blood viscosity

Fundación Clínica Médica Sur, A.C